UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000015053
Receipt number R000017515
Scientific Title Management of Rapid Heart Rate in Patients With Atrial Fibrillation/Flutter and Left Ventricular Dysfunction -Randomized Controlled Trial of Landiolol vs. Diltiazem-
Date of disclosure of the study information 2014/09/15
Last modified on 2018/09/05 11:33:18

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Management of Rapid Heart Rate in Patients With
Atrial Fibrillation/Flutter and Left Ventricular Dysfunction
-Randomized Controlled Trial of Landiolol vs. Diltiazem-

Acronym

Randomized Controlled Trial of Landiolol vs. Diltiazem

Scientific Title

Management of Rapid Heart Rate in Patients With
Atrial Fibrillation/Flutter and Left Ventricular Dysfunction
-Randomized Controlled Trial of Landiolol vs. Diltiazem-

Scientific Title:Acronym

Randomized Controlled Trial of Landiolol vs. Diltiazem

Region

Japan


Condition

Condition

Heart failure, Atrial Fibrillation/Flutter

Classification by specialty

Medicine in general Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evalutation of safety and efficacy of therapeutic drugs

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The primary efficacy endpoint is the percentage of patients
with both a HR <110 beats/min and more than 20% decrease from
baseline at 2 h after administration.
The primary efficacy endpoint is the percentage of patients with severe hypotension, bradycardia.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Landiolol

Interventions/Control_2

Diltiazem

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

The main inclusion criteria were:
male or female inpatients aged more than 20 years; New York Heart
Association (NYHA) class III or IV; and AF/AFL with an LV
ejection fraction (EF) of 25 to 50% and more than 120 beats/min (HR).

Key exclusion criteria

The main exclusion criteria were: necessity for electrical cardioversion;
serious valve stenosis; confirmed or suspected hyperthyroidism;
implantable cardiac pacemaker and/or implantable
defibrillator; necessity for mechanical ventilation; and
cardiogenic shock (systolic blood pressure (BP) <90 mmHg).

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Takeshi Tada

Organization

Kurashiki Central Hospital

Division name

Cardiology

Zip code


Address

Miwa1-1-1, Kurashiki, Okayama

TEL

086-422-0210

Email

yk13983@kchnet.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yuichi Kawase

Organization

Kurashiki Central Hospital

Division name

Cardiology

Zip code


Address

Miwa1-1-1, Kurashiki, Okayama

TEL

086-422-0210

Homepage URL


Email

yk13983@kchnet.or.jp


Sponsor or person

Institute

Kurashiki Central Hospital

Institute

Department

Personal name



Funding Source

Organization

Kurashiki Central Hospital

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 09 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Terminated

Date of protocol fixation

2014 Year 08 Month 25 Day

Date of IRB


Anticipated trial start date

2014 Year 09 Month 15 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 09 Month 04 Day

Last modified on

2018 Year 09 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000017515


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name